Meet SOHO 2026 YIP recipient: Maria Felix Torres, MD
During her residency in the United States, Dr. Torres became even more intrigued by the field. “I was able to see the impact
SOHO 2026
News
Young Investigator Program
Multiple Myeloma
News
FDA accepts NDA for mezigdomide combo in relapsed or refractory myeloma
The US Food and Drug Administration has accepted a new drug application for mezigdomide in combination with carfilzomib and dexamethasone (MeziKd) in patients
Focus on CELMoDs
Past Roundtable Discussions
Multiple Myeloma
Roundtable Discussions
Video Interviews
What are the distinguishing features of CELMoDs?
In this roundtable discussion on myeloma and CELMoDs, the panel discuss mechanism of action, overcoming drug resistance, and other distinguishing features of this
EHA 2026
Meetings / Conferences
Myeloproliferative Neoplasms
Primary Myelofibrosis
Video Interviews
Early-phase trial data of INCA033989 shows durable responses in MF
Claire Harrison, MD, deputy chief medical officer at the Guy's and St. Thomas' NHS Foundation in the United Kingdom, discusses results from the
Ambassador Program
Leukemia
Acute Lymphoblastic Leukemia
News
Society Updates
Anthony Goldstone built a transplant program. It started in a broom cupboard.
At age 28, he was a senior registrar in clinical and laboratory haematology at Addenbrooke’s Hospital in Cambridge. After earning his MRCPath at
ASCO 2026
Trending now
News
Pemivibart safe, effective for prevention of COVID-19 in immunocompromised cancer patients
The study assessed the safety and outcomes of pemivibart in the oncology subset from the open-label, single-arm, immunocompromised Cohort A of the phase
Leukemia
News
FDA approves pivekimab sunirine-pvzy for BPDCN
The drug had earlier received the FDA’s breakthrough designation and orphan drug designation, making the application eligible for priority review. Efficacy was evaluated
Lymphoma
Indolent B-Cell Lymphomas
No OS benefit to adding bendamustine to rituximab for marginal zone lymphoma
As a first-line treatment for patients with marginal zone lymphoma, the combination of bendamustine with rituximab (BR) conferred no advantage in overall survival
Soho Print
SOHO Insider 2026 print issue May/June
This issue of SOHO Insider features an article on US patient representation in global trials, an interview with Dr. Naval Daver, and photos
Lymphoma
Mantle Cell Lymphoma
FDA grants accelerated approval to sonrotoclax for relapsed or refractory mantle cell lymphoma
The US Food and Drug Administration has granted accelerated approval to sonrotoclax, a BCL-2 inhibitor, for adults with relapsed or refractory mantle cell